Asahi Kasei Pharma

Asahi Kasei Pharma Corporation (AKP) is a fully integrated Japanese pharmaceutical company with capabilities in R&D, manufacturing and commercialization. 

AKP has a well established management team for clinical trials, giving us a strong track records to obtain market approvals for products and an experienced nationwide sales force in Japan.

AKP has successfully partnered with large and small organizations to develop and commercialize a variety of innovative treatments including Famvir, Flivas, Toledomin, Xiaflex, Reclast, Kevzara and Plaquenil as well as our own original products such as Teribone and Recomodulin.

Our focus areas are autoimmune diseases, renal diseases, hematological diseases, rare GI diseases, refractory infectious diseases, and pulmonary diseases.

We are seeking early-stage in-licensing opportunities in the field of Autoimmune diseases, nephrology, transplan& adjacent area, and refractory immune and renal rare diseases for global market. 

Address

Tokyo
Japan
Loading